Drug-Inducible Gene Therapy Yields Encouraging Preliminary Results in High-Grade Glioma Trial
In a recent clinical trial in patients with recurrent high-grade gliomas, investigators from the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center set out to test the safety and effectiveness of controlling the powerful immunotherapy human interleukin-12 (hIL-12) by using an oral activator to control when the gene gets turned on. While hIL-12 can stimulate many branches of the immune system, previous clinical trials that leveraged it were halted because of toxicity.
Read More